in past times several years, the UK has witnessed a revolution in clinical bodyweight‑decline therapies — with the introduction of semaglutide (Wegovy®) to the growing reputation of tirzepatide (Mounjaro®). Now, One more identify is drawing attention in both of those clinical and community overal